Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Multiple sclerosis

Reprogramming the immune repertoire with alemtuzumab in MS

Results from two phase III trials show the potency of alemtuzumab—a T-cell and B-cell depleting antibody—in reducing clinical and paraclinical measures of disease activity in relapsing–remitting multiple sclerosis. The effects of this immunotherapeutic agent highlight the relevance of T lymphocytes in the early pathogenesis of disease.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Klotz, L., Meuth, S. G. & Wiendl, H. Immune mechanisms of new therapeutic strategies in multiple sclerosis—a focus on alemtuzumab. Clin. Immunol. 142, 25–30 (2012).

    CAS  Article  PubMed  Google Scholar 

  2. CAMMS223 Trial Investigators. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786–1801 (2008).

  3. Cohen, J. A. et al. Alemtuzumab versus interferon β-1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380, 1819–1828 (2012).

    CAS  Article  PubMed  Google Scholar 

  4. Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380, 1829–1839 (2012).

    CAS  Article  PubMed  Google Scholar 

  5. Jones, J. L. et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 119, 2052–2061 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Thompson, S. A., Coles, A. J. & Jones, J. L. Peripheral expansion dominates early T cell reconstitution following alemtuzumab treatment of multiple sclerosis—implications for secondary autoimmunity [abstract P457]. Mult. Scler. 17 (10 Suppl.), S191–S192 (2011).

    Google Scholar 

  7. Jones, J. L., Compston, D. A. & Coles, A. J. Predicting autoimmunity following treatment of multiple sclerosis with alemtuzumab [abstract P1009]. Mult. Scler. 17 (10 Suppl.), S459 (2011).

    Google Scholar 

  8. Coles, A. J. et al. Alemtuzumab versus interferon β-1a in early relapsing–remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 10, 338–348 (2011).

    CAS  Article  PubMed  Google Scholar 

  9. Walsh, M., Chaudry, A. & Jayne, D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann. Rheum. Dis. 67, 1322–1327 (2008).

    CAS  Article  PubMed  Google Scholar 

  10. Coles, A. J. et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78, 1069–1078 (2012).

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Heinz Wiendl or Bernd Kieseier.

Ethics declarations

Competing interests

H. Wiendl has received honoraria for lecturing, council and advisory boards, and travel expenses for attending meetings from Bayer Health Care, Biogen Idec/Elan Corporation, CSL Behring, Fresenius, Lilly, Lundbeck, Merck Serono, Novartis, Genzyme/Sanofi Aventis, and TEVA. He has served or serves as a consultant for Biogen Idec, Genzyme/Sanofi-Aventis, Merck Serono, Novartis Pharma, and NovoNordisk, and receives research support from Bayer Schering Pharma, Biogen Idec/Elan Corporation, Fresenius, Genzyme/Sanofi, Merck Serono, Novartis, Novo Nordisk, and TEVA. B. Kieseier has received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Schering, Biogen Idec, CSL Behring, Genzyme/Sanofi Aventis, Grifols, Merck Serono, Novartis, Roche, Sanofi Aventis, Talecris, and TEVA Neurosciences.

Supplementary information

Supplementary Figure 1

Four types of immunotherapeutic approaches and their effect on the immunopathogenesis of multiple sclerosis. (PDF 251 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wiendl, H., Kieseier, B. Reprogramming the immune repertoire with alemtuzumab in MS. Nat Rev Neurol 9, 125–126 (2013). https://doi.org/10.1038/nrneurol.2013.2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2013.2

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing